Welcome to our dedicated page for Ascent Industries Co. SEC filings (Ticker: ACNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ascent Industries Co. (ACNT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Ascent describes itself as a specialty chemicals platform focused on tailored, performance-driven chemical solutions, and its filings give detailed insight into how this business is structured and financed.
Key documents include periodic reports such as Forms 10-K and 10-Q, where Ascent presents financial statements, segment information, and discussions of factors affecting its specialty chemicals operations and Chemicals-as-a-Service (CaaS) model. These filings also elaborate on the company’s use of non-GAAP measures like EBITDA and Adjusted EBITDA, with reconciliations to GAAP metrics.
Current reports on Form 8-K highlight material events, including amendments to the company’s credit facility, divestitures of Bristol Metals, LLC (BRISMET) and American Stainless Tubing, Inc. (ASTI), lease modifications related to former tubular facilities, adoption of Rule 10b5-1 trading plans for share repurchases, and announcements of financial results. Other filings, such as proxy statements on Schedule 14A, provide information on director elections, advisory votes on executive compensation, and auditor ratification.
On Stock Titan, users can view these filings alongside AI-powered summaries that explain the key points of lengthy documents, helping to interpret complex credit facility amendments, lease agreements, or capital allocation disclosures. Real-time updates from EDGAR ensure that new Ascent filings appear promptly, while access to historical reports and, where applicable, insider transaction filings such as Form 4 allows investors to examine trends in governance, capital structure, and management’s reported decisions over time.
Ascent Industries Co. expanded its Board of Directors from five to seven members and appointed specialty chemicals veterans Carmen J. Giannantonio and Jeremy F. Rohen as independent directors, effective April 1, 2026. Both will serve on key committees, adding finance, M&A, and distribution expertise.
The company also adopted a Rule 10b5-1 trading plan to repurchase up to 1,750,000 shares of its common stock between March 31, 2026 and May 11, 2026 under its existing stock repurchase program. Director John P. Schauerman will not stand for re-election but will serve through the 2026 Annual Meeting.
Ascent Industries Co. filed a shelf registration to offer up to $100,000,000 of securities, consisting of common stock, debt securities, warrants, purchase contracts, rights and units, to be sold from time to time in one or more offerings.
The prospectus is a general description; specific terms, amounts, prices and distribution methods will be set forth in prospectus supplements. Net proceeds are expected to be used for general corporate purposes, including capital expenditures, debt reduction, acquisitions or working capital.
ASCENT INDUSTRIES CO. reported compensation-related equity activity for V.P. Business Operations Harshil Vipul Shah. On March 26, 2026, he acquired 5,896 shares of common stock at $12.84 per share as a grant, after performance stock units vested at 109% of the target award based on adjusted EBITDA criteria. On March 27, 2026, 2,096 shares at $12.85 per share were disposed of to cover tax withholding obligations. Following these transactions, he directly holds 6,894 shares of common stock.
ASCENT INDUSTRIES CO. vice president of sales and business development Anthony X. Pan reported equity compensation and related tax withholding in company stock.
On March 26, he acquired 5,028 shares of common stock at $12.84 per share as a grant. Footnotes explain that performance stock units vested at 109% of the target award based on adjusted EBITDA performance.
On March 27, 1,733 shares at $12.85 per share were disposed of to cover tax withholding obligations, a non‑market transaction. After these entries, he held 23,946 shares directly, plus indirect holdings of 2,693 shares held by his spouse and 550 shares held by his mother.
ASCENT INDUSTRIES CO. reported that its General Counsel, Kimberly Portnoy, received a compensation-related equity award and had shares withheld to cover taxes. On March 26, she acquired 5,896 shares of common stock at $12.84 per share as a grant tied to performance stock units that vested at 109% of the target award based on adjusted EBITDA performance. On March 27, 1,735 shares at $12.85 per share were disposed of as a tax-withholding transaction, not an open-market sale. After these transactions, she directly owned 7,321 shares of ASCENT INDUSTRIES common stock.
Ascent Industries Co. vice president of finance Kenneth Wayne Herring Jr. reported a stock-based compensation event and related tax withholding. He received a grant of 3,750 shares of common stock tied to performance stock units that vested at 109% of target based on adjusted EBITDA. To cover tax obligations from this vesting, 1,350 shares were disposed of through tax withholding, not an open-market sale. Following these transactions, he holds 4,470.699 common shares directly.
ASCENT INDUSTRIES CO. vice president of operations – chemicals, Srinivas Ravi Ramesh, received a grant of 4,610 shares of common stock at $12.84 per share as a stock award. The performance stock units vested at 109% of the target amount based on adjusted EBITDA performance.
To cover related tax withholding obligations, 1,551 shares of common stock were disposed of at $12.85 per share, a tax-withholding transaction rather than an open-market sale. After these compensation-related transactions, he directly holds 21,518 shares of Ascent Industries common stock.
Ascent Industries Co. furnished an investor presentation outlining its transformation into a focused specialty chemicals company and updating investors on recent performance and capital allocation. The materials emphasize domestic manufacturing, a management team with prior turnaround experience, and a customer-centric Chemicals-as-a-Service model spanning life sciences, performance materials, and multiple industrial end markets.
Financially, consolidated adjusted EBITDA from continuing operations improved from $(4.7) million in 2024 to $(0.6) million in 2025, with the adjusted EBITDA margin narrowing from (5.8)% to (0.8)%. Within the specialty chemicals segment, adjusted EBITDA rose from $6.3 million in 2024 to $8.1 million in 2025, with segment margin increasing from 7.8% to 10.8%. The company also highlights portfolio optimization, including asset sales, and repurchase of 7.4% of outstanding shares in 2025, as well as roughly $63 million of debt capacity and about $30 million of cash to support disciplined M&A and growth investments.